CANSINOBIO's stock price surged 9.68% during intraday trading on Wednesday, following the release of its annual financial results.

The company reported full-year revenue of RMB 1.059 billion, a 28.43% year-on-year increase, and a profit attributable to owners of RMB 27.87 million, marking a turnaround from a loss in the previous year. Additionally, CANSINOBIO announced a shareholder dividend return plan for the next three years with a focus on cash dividends.

The performance growth was primarily fueled by sustained revenue increases from its core product, Menhycia, China's first quadrivalent meningococcal conjugate vaccine. The company's strategies in innovation, commercialization, cost reduction, and operational efficiency enhancements have contributed to the positive results.